Do PPAR‐Gamma Agonists Have a Future in Parkinson′ s Disease Therapy?
Thiazolidinediones (TZDs) are peroxisome proliferator‐activated receptor (PPAR)‐γ
agonists commonly used as insulin‐sensitizing drugs for the treatment of type 2 diabetes. In …
agonists commonly used as insulin‐sensitizing drugs for the treatment of type 2 diabetes. In …
Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?
A Carta, A Pisanu, E Carboni - PARKINSON'S DISEASE, 2011 - iris.unica.it
Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR)-γ agonists
commonly used as insulin-sensitizing drugs for the treatment of type 2 diabetes. In the last …
commonly used as insulin-sensitizing drugs for the treatment of type 2 diabetes. In the last …
[HTML][HTML] Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?
AR Carta, A Pisanu, E Carboni - Parkinson's Disease, 2011 - ncbi.nlm.nih.gov
Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR)-γ agonists
commonly used as insulin-sensitizing drugs for the treatment of type 2 diabetes. In the last …
commonly used as insulin-sensitizing drugs for the treatment of type 2 diabetes. In the last …
Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?
AR Carta, A Pisanu, E Carboni - Parkinson's Disease, 2011 - cir.nii.ac.jp
抄録< jats: p> Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor
(PPAR)-< jats: italic> γ</jats: italic> agonists commonly used as insulin-sensitizing drugs for …
(PPAR)-< jats: italic> γ</jats: italic> agonists commonly used as insulin-sensitizing drugs for …
[PDF][PDF] Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?
AR Carta, A Pisanu, E Carboni - 2011 - Citeseer
Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR)-γ agonists
commonly used as insulinsensitizing drugs for the treatment of type 2 diabetes. In the last …
commonly used as insulinsensitizing drugs for the treatment of type 2 diabetes. In the last …
Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?
AR Carta, A Pisanu, E Carboni - Parkinson's disease, 2011 - pubmed.ncbi.nlm.nih.gov
Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR)-γ agonists
commonly used as insulin-sensitizing drugs for the treatment of type 2 diabetes. In the last …
commonly used as insulin-sensitizing drugs for the treatment of type 2 diabetes. In the last …
Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?
AR Carta, A Pisanu, E Carboni - Parkinson's Disease …, 2011 - search.ebscohost.com
Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR)-γ agonists
commonly used as insulinsensitizing drugs for the treatment of type 2 diabetes. In the last …
commonly used as insulinsensitizing drugs for the treatment of type 2 diabetes. In the last …
[PDF][PDF] Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?
AR Carta, A Pisanu, E Carboni - 2011 - pdfs.semanticscholar.org
Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR)-γ agonists
commonly used as insulinsensitizing drugs for the treatment of type 2 diabetes. In the last …
commonly used as insulinsensitizing drugs for the treatment of type 2 diabetes. In the last …
[PDF][PDF] Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?
AR Carta, A Pisanu, E Carboni - 2011 - researchgate.net
Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR)-γ agonists
commonly used as insulinsensitizing drugs for the treatment of type 2 diabetes. In the last …
commonly used as insulinsensitizing drugs for the treatment of type 2 diabetes. In the last …
Do PPAR-gamma agonists have a future in Parkinson's disease therapy?
AR Carta, A Pisanu, E Carboni - Parkinson's Disease, 2011 - go.gale.com
Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR)-[gamma]
agonists commonly used as insulin-sensitizing drugs for the treatment of type 2 diabetes. In …
agonists commonly used as insulin-sensitizing drugs for the treatment of type 2 diabetes. In …